Our Assembly-Line Future?
By Stuart A. Newman,
Counterpunch
| 07. 31. 2018
Human civilization has taken an important turn with the publication of a new report by the Nuffield Council, the semi-official bioethics agency of the United Kingdom. The document, two years in preparation, gives the go-ahead to genetically engineer human beings at the embryonic stages of development. The report stated: “There is potential for heritable genome editing interventions to be used at some point in the future in assisted human reproduction, as a means for people to secure certain characteristics in their children.” If history is a guide, the U.S. will not lag far behind the U.K. in following this dangerous path.
The U.K. pioneered human genetic engineering by approving, earlier this year, a technique to construct embryos using parts of the eggs of two different women, along with a man’s sperm, to create “three-person embryos.” Though deceptively promoted as “mitochondrial transfer,” the procedure really involves transferring around 20 thousand genes from a woman with impaired mitochondria into another woman’s egg. The accurate “three-person” designation was only widely used in the scientific literature after the procedure became legal. Similar misrepresentations of...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...